Review of biomarker systems as an alternative for early diagnosis of ovarian carcinoma

• A. Srivastava ^[1] ; A. Gupta ^[1] ; S. Patidar ^[1]
  1. [1] Delhi Technological University

     Delhi Technological University

     India

     
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 23, Nº. 10, 2021, págs. 1967-1978
• Idioma: inglés
• Enlaces
  • Texto completo (pdf)
• Resumen

  • Early diagnosis of ovarian carcinoma is bound to boost the long-term endurance rate of the patients. Most ovarian tumors happen post menopause when the ovaries have no vital operation and therefore irregular ovarian role causes no signs. According to Muinao T. et al. (Heliyon. 5(12):e02826, 2019), if we consider the frequency of ovarian carcinoma to be moderate, a screening technique must accomplish a base specificity of 99.6% and sensitivity of over 75%. The classification and approval of early diagnostic biomarkers explicit to ovarian carcinoma are essentially required. Prevailing methods for early diagnosis of ovarian carcinoma incorporate TVS, biological marker examination, or a blend of the two or other. In recent years, it has been revealed that a combination of at least two biomarkers has beaten single biomarkers in measures for early diagnosis of the illness. In the present document, we survey the ongoing exploration of innovative characteristic methodologies and possible panels of carcinoma biological markers for the early diagnosis of ovarian carcinoma and discuss biomarkers as the plausible apparatus for model improvement and other progressed approaches as an effective alternative to the prevailing methods for early diagnosis of this dreadful disease to evade bogus analysis and inordinate expense.